A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females 18 years of age and older
Diagnosed with NMIBC
Prescribed intravesical valrubicin to treat NMIBC
Understood and signed Informed Consent to participate
You may not be if
None
Clareo Health | A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
